News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

December 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 27, 2024 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 12, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
November 5, 2024 Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
October 26, 2024 Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
October 22, 2024 Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
October 16, 2024 Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 4, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 25, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 20, 2024 Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination